Rheumatology Drug Updates: Efficacy Studied Following Accelerated Drug Approvals; Plus Secukinumab Meets Benchmark for Psoriasis

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

1. Naci H, Smalley K, Kesselheim A. Characteristics of preapproval and postapproval studies for drugs granted accelerated approval by the U.S. Food and Drug Administration. JAMA. 2017 Aug 15;318(7):626–636.
2. Novartis. Press release: Novartis’ Cosentyx sets new benchmark in psoriasis with robust five-year sustained Phase III efficacy and safety data. 2017 Sep 19.